Curis (NASDAQ:CRIS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a report released on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, March 31st.

Curis Trading Down 2.8 %

Shares of NASDAQ CRIS opened at $2.41 on Wednesday. The stock has a market capitalization of $20.46 million, a PE ratio of -0.31 and a beta of 3.51. Curis has a 12-month low of $1.02 and a 12-month high of $16.93. The stock’s fifty day simple moving average is $2.09 and its two-hundred day simple moving average is $3.19.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Monday, March 31st. The biotechnology company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.11. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%. The firm had revenue of $2.70 million during the quarter, compared to analyst estimates of $2.04 million. On average, equities analysts predict that Curis will post -7.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Curis

A number of large investors have recently bought and sold shares of CRIS. Wealthquest Corp acquired a new position in Curis during the first quarter valued at $1,542,000. M28 Capital Management LP lifted its holdings in Curis by 23.5% in the fourth quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 99,108 shares during the period. Bleichroeder LP boosted its position in Curis by 1,982.2% in the 4th quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock worth $1,593,000 after purchasing an additional 495,540 shares in the last quarter. CM Management LLC grew its stake in shares of Curis by 83.3% during the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after purchasing an additional 100,000 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Curis in the 4th quarter valued at $607,000. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.